Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medical composition containing riluzole

A composition, the technology of riluzole, applied in the field of pharmaceutical composition, can solve the problems of low bioavailability, unstable stability, easy layering of emulsion, etc., and achieve the effect of improving dissolution rate, easy to carry, and convenient to take

Inactive Publication Date: 2009-03-25
AVENTIS PHARMA HAINAN
View PDF1 Cites 63 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] CN1780620 discloses the use of riluzole in the treatment and / or prevention of local medicines for neurological or brain diseases and / or injuries, as well as the local combined preparations containing riluzole and / or damage-effective agents. In the patent examples Disclosed is a group of emulsions containing riluzole, containing riluzole, glyceryl monostearate 60, cetyl alcohol, medium carbon chain triglycerides, white petrolatum, polyethylene glycol-20-glycerol monostearate Ester, propylene glycol, purified water, but the emulsion has the disadvantages of easy layering of the emulsion, low bioavailability, and unstable stability. This experiment aims to develop an oral solid dosage form to improve the bioavailability and stability of the drug

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medical composition containing riluzole

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019]

[0020] Preparation:

[0021] Weigh the prescribed amount of riluzole, mannitol, microcrystalline cellulose, and L-HPC and mix evenly, weigh polyvinylpyrrolidone to make an aqueous solution as a binder for granulation, add the rest of L-HPC, and add stearic acid Magnesium, mixed, compressed into tablets, ready to use.

Embodiment 2

Total 100

[0024] Preparation:

[0025] Weigh the prescribed amount of riluzole, starch, sorbitol, and crospovidone and mix evenly; weigh hydroxypropyl methylcellulose to make an aqueous solution as a binder to granulate; add micropowder silica gel to mix evenly; pack into capsules Instantly.

Embodiment 3

Total 100

[0028] Preparation:

[0029] Weigh the prescribed amount of riluzole, lactose, microcrystalline cellulose, and partially cross-linked povidone and mix evenly, weigh hydroxypropyl methylcellulose to make an aqueous solution as a binder for granulation, and add the remaining part of cross-linked polyvinyl alcohol Vitamin ketone, adding magnesium stearate, mixing, tableting, to obtain.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a stable medicinal combination which contains active ingredient riluzole and pharmaceutical auxiliary material. The medicine combination is mainly used for the clinical treatment of amyotrophic lateral sclerosis.

Description

technical field [0001] The invention designs a pharmaceutical composition, especially a pharmaceutical composition containing riluzole. Background technique [0002] Riluzole (2-amino-6-trifluoromethoxy-benzothiazole) is a benzothiazole compound with clear pharmacological activity, which is mainly produced by inhibiting the activation of sodium channels and reducing the release of glutamate Neuroprotective, anticonvulsant, antidepressant, sedative and anti-physical dependence and other pharmacological effects. [0003] Amyotrophic lateral sclerosis is a motor neuron disease characterized by muscle weakness, muscle contractures, fasciculations, and atrophy that affects the muscles of the throat and throat, making speech and swallowing difficult; Involvement of the respiratory muscles, resulting in dyspnea and death. Although the pathogenesis of ALS has not been fully elucidated, it has been theorized that glutamate is responsible for cell death in this disease. Riluzole ex...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/428A61K47/26A61K47/36A61K47/38A61K47/02A61K47/30A61K47/32A61P25/00A61P25/08A61P25/24A61P25/20A61K9/02A61K9/20
Inventor 吕青远
Owner AVENTIS PHARMA HAINAN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com